In this article, we will discuss Golimumab and Autoimmune Disorders and Autoantibodies. So, let’s get started.
Golimumab and Autoimmune Disorders and Autoantibodies
The use ofTNF-blockers, including Golimumab, has been associated with the formation of autoantibodies and, rarely, with the development of a lupus-like syndrome. In the controlled Phase 3 trials in patients with RA, PsA, and AS through Week 14, there was no association of Golimumab treatment and the development of newly positive anti-dsDNA antibodies.